NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
AUREA Trial’s Decisive 90 Days: DAPT Shows Advantage Over OAC in Cerebral Protection post-TAVI?
EuroIntervention / X
Jul 11, 2025, 17:32

AUREA Trial’s Decisive 90 Days: DAPT Shows Advantage Over OAC in Cerebral Protection post-TAVI?

EuroIntervention, an official Journal of Euro PCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), recently shareda post on X:

”In this randomized trial, OAC did not outperform DAPT in preventing cerebral microembolism post-TAVI. DW-MRI findings suggest DAPT may lead to lower total embolic volume at 90 days.”

Read the article here.

EuroInterention recently shared the AUREA trial data on use of OAC and DAPT: ‘A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial‘ published by Victor Alfonso Jimenez Diaz et al.

In the AUREA randomized clinical trial evaluating post-TAVI antithrombotic strategies, oral anticoagulation (OAC) did not outperform dual antiplatelet therapy (DAPT) in preventing cerebral microembolism.

Among patients without a formal indication for anticoagulation, a 3-month OAC regimen failed to demonstrate benefit over DAPT in reducing subclinical brain infarcts.

Diffusion-weighted MRI at 90 days revealed a lower mean embolic volume in patients receiving DAPT compared to those on acenocoumarol, suggesting DAPT may offer superior cerebral protection in this population.

AUREA Trial's Decisive 90 Days: DAPT Shows Advantage Over OAC in Cerebral Protection post-TAVI?

Hemostasis Today, daily news on stroke management.

Antithrombotic Strategies AUREA trial Cerebral microembolism DAPT EAPCI EuroIntervention EuroPCR Health Hematology Hemostasis Today Medicine OAC Post-TAVI stroke Victor Alfonso Jimenez Diaz
NewsFeed